Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFRvIII CAR T cells in newly diagnosed GBM
NCT02664363Phase 1Terminated
- Start
- Feb 2017
- Primary completion
- Sep 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFRvIII-CAR T cells in glioblastoma (GBM) and Gliosarcoma (GS). Primary endpoint: Maximally Tolerated Dose. Started Feb 2017; status: terminated.
02
Drugs
EGFRvIII-CAR T cells
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02664363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664363.